Major Market Shift in Peripheral Neuropathy Industry: Technological Advancements In Peripheral Neuropathy Screening Enhanced Market

What Is the Forecasted Market Size and Growth Rate for the Peripheral Neuropathy Market?
The size of the peripheral neuropathy market has seen a rapid expansion in recent years, set to increase from $4.09 billion in 2024 to $4.62 billion in 2025, representing a compound annual growth rate (CAGR) of 13.2%. This growth during the historical period is due to a variety of factors including the rising prevalence of chronic illnesses such as diabetes, increased public knowledge about neuropathic pain management, a surge in the global aging population, the growth of the healthcare infrastructure sector, the emergence of specialized treatment facilities, government-led initiatives for enhanced neurological healthcare services, and the increasing adoption of innovative treatment options.

In the coming years, the peripheral neuropathy market is set to experience a significant surge, reaching $7.52 billion in 2029 with a compound annual growth rate (CAGR) of 12.9%. This rapid expansion during the projected period is linked to the sustained increase in chronic diseases such as cancer and diabetes, the evolution of pharmacological treatments designed to target neuropathic pain pathways, enhanced investment in research and development of cutting-edge treatment methods, the incorporation of digital healthcare solutions for remote monitoring and bespoke management of neuropathic signs, a rising emphasis on patient-specific care paradigms, and better access to comprehensive healthcare facilities. Notable trends for the forecast period include an uptick in the implementation of personalized treatments, an expansion in the usage of wearable technology for real-time observation of neuropathic signs and medication, the broadening of telemedicine facilities for distance consultations and follow-ups, the creation of targeted treatments addressing unique neuropathic pain pathways and mechanisms, progress in regenerative medicine practices, incorporation of digital therapy platforms for cognitive behavioral therapy and mindfulness-based strategies, and technological leaps in diagnostic tools for early identification and tracking of peripheral neuropathy.

What Are the Forces Behind the Rapid Growth of the Peripheral Neuropathy Market?
The peripheral neuropathy market is projected to grow, fuelled by escalating diabetes cases. Diabetes is a chronic disease marked by elevated blood glucose due to the body's unsuccessful production or usage of insulin. A rise in diabetes patients is predominantly attributed to factors like increased obesity rates, sedentary lifestyles, and ageing populations. Diabetes can induce peripheral neuropathy by causing nerve damage from prolonged high glucose levels in the blood, resulting in symptoms like extremity pain, numbness, and tingling. It's critical to monitor and control blood sugar levels effectively to prevent or decelerate this complication's progression. For example, The British Diabetic Association revealed in a report in April 2023 that 4.3 million individuals in the U.K. have diabetes diagnoses. There was an increase of 148,951 cases in the registration data for 2021-22 compared to 2020-21. Moreover, over 2.4 million U.K. residents are at an elevated risk of type two diabetes. Hence, this surge in diabetes cases is stimulating the peripheral neuropathy market's growth.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16507&type=smp

Which Businesses Are at the Forefront of Peripheral Neuropathy Market Development?
Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Asahi Kasei Corporation, Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, ACI Limited, Lexicon Pharmaceuticals, Solasia Pharma KK, Helixmith Co. Ltd., PledPharma AB

What Are the Latest Innovations in the Peripheral Neuropathy Market?
Leading businesses in the peripheral neuropathy market are concentrating their efforts on creating innovative solutions like point-of-care devices, for better diagnosis and management of the disorder. This includes the application of point-of-care peripheral neuropathy quantitative screening tests as a fast and effective way of identifying nerve damage in a person's extremities, often associated with diabetes. For example, in January 2023, NeuroMetrix Inc, a prominent American manufacturer of non-invasive medical devices, introduced their DPNCheck 2.0, a point-of-care device specifically designed to identify peripheral neuropathy. This device employs nerve conduction technology to detect the comprehensive degeneration of peripheral nerves, which can evolve into severe conditions like diabetic peripheral neuropathy (DPN). Its ability to provide quick patient evaluations via quantitative peripheral nerve function measurement makes it a more accurate and efficient alternative compared to traditional methods, such as the monofilament and tuning fork tests.

How Is the Peripheral Neuropathy Market Segmented?
The peripheral neuropathy market covered in this report is segmented -

1) By Type: Chemotherapy-Induced, Diabetic, Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated, Idiopathic
2) By Diagnosis: Blood Test, Biopsy, Imaging, Other Diagnosis
3) By Treatment: Medications, Antidepressants, Anti-Seizure Medication, Pain Reliever, Topical Treatment, Therapies, Nerve Stimulation, Plasma Exchange, Physical Therapy, Other Treatments
4) By End-User: Hospitals, Clinics, Ambulatory Centers

Subsegments:
1) By Chemotherapy-Induced: Taxane-Induced Peripheral Neuropathy, Platinum-Based Drug-Induced Neuropathy, Other Chemotherapy-Induced Neuropathies
2) By Diabetic: Type 1 Diabetes-Induced Peripheral Neuropathy, Type 2 Diabetes-Induced Peripheral Neuropathy
3) By Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated: HIV-Associated Peripheral Neuropathy, AIDS-Related Peripheral Neuropathy
4) By Idiopathic: Acute Idiopathic Neuropathy, Chronic Idiopathic Neuropathy

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Where Is the Peripheral Neuropathy Market Growth Most Prominent?
North America was the largest region in the peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Peripheral Neuropathy Global Market Report?

- Market Size Analysis: Analyze the Peripheral Neuropathy Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Peripheral Neuropathy Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Peripheral Neuropathy Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Peripheral Neuropathy Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16507

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.